Interestingly, disease-modifying drugs (DMDs) such as dimethyl fumarate (DMF) and interferon-beta (IFN-β) have been shown to restore Treg responsiveness in T cells from MS patients by normalizing PKB/c-Akt activation [4,5]. This evidence concerns the gene IFNB1 and myeloid sarcoma.